[{"from": "human", "value": "Describe this molecule. [C][N][C][=C][Branch1][Branch1][C][=N][Ring1][Branch1][N][C][=N][C][=C][Branch1][=Branch2][C][=Branch1][Branch1][=C][N][Ring1][Branch1][Cl][C][=Branch1][Ring2][=N][Ring1][#Branch2][O][C][C@H1][C][N][Branch1][#Branch1][C][C@@H1][Ring1][Branch1][O][C][C][=Branch1][C][=O][C][=C]"}, {"from": "gpt", "value": "The molecule is an orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity. EGFR inhibitor PF-06459988 specifically binds to and inhibits mutant forms of EGFR, including the secondary acquired resistance mutation T790M, which prevents EGFR-mediated signaling and leads to cell death in EGFRm-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that are seen with the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization."}]